Latest Kaiser Health News Stories
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners’ questions about health policy and politics.
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
The opioid epidemic has increased the number of donated organs. Until recently, though, organs from donors who died of drug overdoses were often discarded because an estimated 30 percent of them were infected with hepatitis C.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
A study published Thursday shows that doctors, dentists and other medical providers cut overall opioid dosages by nearly 10 percent after receiving notification of a death from a medical examiner and information on safe prescribing.
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
States are passing laws that limit a doctor’s ability to prescribe opioids. Doctors and patients alike are wrestling with what that means in cases of chronic pain.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Did OxyContin maker admit opioids can be dangerous even when patients take them as prescribed — then walk it back?
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.